Nektar Therapeutics (NASDAQ:NKTR)

CAPS Rating: 2 out of 5

A biopharmaceutical company which develops breakthrough products that make a difference in patients' lives. It creates differentiated, innovative products by applying its platform technologies to established or novel medicines.

Recs

0
Player Avatar Aiden1976 (94.29) Submitted: 4/9/2008 12:32:59 PM : Outperform Start Price: $5.06 NKTR Score: +36.47

Because Pfizer want to stop sell the product(inulin inhaler) with NKTR, and the stock got plunge down hard by about 25%. But it will search for another partner to continue sell the product. It might be down for awhile, but I will come back up.

Featured Broker Partners


Advertisement